TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange. When a viewer asks if Biogen's (BIIB) horseman has fallen off the horse, Cramer says he needs to reevaluate the company. Biogen, one of Cramer's 'Four Horsemen,' disappointed investors by lowering its full-year earnings and sales forecast because it no longer expects its multiple sclerosis drug Tecfidera to grow as expected. While he reconsiders the stock, Cramer stresses that he likes Regeneron (REGN), Celgene (CELG) and Gilead (GILD) much more than Biogen here. Another viewer notes that Inotek Pharmaceuticals (ITEK) just had a positive phase two meeting with the U.S. Food and Drug Administration and asks if the stock is a buy here. Cramer explains that the smart money was already there before the company's meeting with the FDA and that the stock would be too risky for him now. When it comes to Sprint (S), Cramer says the stock is a sell. He says it's a balance sheet issue for Sprint and he believes the company needs to raise a lot of money. He also weighs in on other names in the space like T-Mobile (TMUS), AT&T (T) and Verizon (VZ). If you have a stock question, tweet it @jimcramer using #CramerQ.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Video
17 Satirical Game of Thrones' Quotes About Investing
Game of Thrones fans prepare for the final episode to premiere Sunday night. Watch the video tribute, as we conjured up quotes for TheStreet Columnists.
Kohl's and 2 Other Retail Earnings That Every Investor Should Watch Next Week
Feeling overwhelmed as the markets gear up for retail earnings palooza? Action Alerts PLUS senior analyst Jeff Marks is watching three key retail earnings.
Why Your Personality Can Be Dangerous to Your Wealth
Find out how your personality can affect your portfolio withdrawal rate.
Nvidia Stops Issuing Full-Year Guidance: How Worried Should Investors Be?
The chipmaker posted a healthy quarter but now is declining to offer longer-term guidance to investors.